ES2989869T3 - Sal sódica cristalina de ácido 5-metil-(6S)-tetrahidrofólico - Google Patents

Sal sódica cristalina de ácido 5-metil-(6S)-tetrahidrofólico Download PDF

Info

Publication number
ES2989869T3
ES2989869T3 ES18715594T ES18715594T ES2989869T3 ES 2989869 T3 ES2989869 T3 ES 2989869T3 ES 18715594 T ES18715594 T ES 18715594T ES 18715594 T ES18715594 T ES 18715594T ES 2989869 T3 ES2989869 T3 ES 2989869T3
Authority
ES
Spain
Prior art keywords
methyl
salt
tetrahydrofolic acid
crystalline
sodium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES18715594T
Other languages
English (en)
Spanish (es)
Inventor
Rudolf Moser
Viola Groehn
Fritz Blatter
Martin Szelagiewicz
Stamm Ruth Boehni
Markus Ruettimann
Giuseppe Lapadula
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Application granted granted Critical
Publication of ES2989869T3 publication Critical patent/ES2989869T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
    • C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES18715594T 2017-03-31 2018-03-28 Sal sódica cristalina de ácido 5-metil-(6S)-tetrahidrofólico Active ES2989869T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17164349 2017-03-31
PCT/EP2018/057900 WO2018178141A1 (en) 2017-03-31 2018-03-28 Crystalline sodium salt of 5-methyl-(6s)-tetrahydrofolic acid

Publications (1)

Publication Number Publication Date
ES2989869T3 true ES2989869T3 (es) 2024-11-28

Family

ID=58464443

Family Applications (1)

Application Number Title Priority Date Filing Date
ES18715594T Active ES2989869T3 (es) 2017-03-31 2018-03-28 Sal sódica cristalina de ácido 5-metil-(6S)-tetrahidrofólico

Country Status (15)

Country Link
US (2) US11185545B2 (pl)
EP (1) EP3609894B1 (pl)
JP (1) JP7285785B2 (pl)
KR (1) KR102665004B1 (pl)
CN (1) CN110475778A (pl)
AU (1) AU2018246265B2 (pl)
CA (1) CA3058287A1 (pl)
DK (1) DK3609894T3 (pl)
ES (1) ES2989869T3 (pl)
FI (1) FI3609894T3 (pl)
HU (1) HUE068578T2 (pl)
PL (1) PL3609894T3 (pl)
PT (1) PT3609894T (pl)
RU (1) RU2019133594A (pl)
WO (1) WO2018178141A1 (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115611899B (zh) * 2022-10-25 2024-06-04 无锡紫杉药业股份有限公司 一种l-5-甲基四氢蝶酸的制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5124452A (en) 1978-07-10 1992-06-23 Bioresearch S.P.A. Process for producing d,1-5-methyltetrahydrofolic acid and its salts
IT1229517B (it) 1989-01-31 1991-09-03 Bioresearch Spa Impiego di acido 5-metiltetraidrofolico, di acido 5 formiltetraidrofolico, e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato adatte ad essere impiegate nella terapia dei disordini depressivi e composizioni farmaceutiche relative.
CH686369A5 (de) 1994-05-09 1996-03-15 Eprova Ag Stabile kristalline (6S)- und (6R)-Tetrahydrofolseure.
ZA968485B (en) 1995-11-01 1997-05-20 Lonza Ag Process for preparing nicotinamide
CH689831A5 (de) 1995-11-07 1999-12-15 Eprova Ag Stabile kristalline Tetrahydrofolsaeure-Salze.
CH693255A5 (de) * 1997-06-13 2003-05-15 Eprova Ag Verwendung von Tetrahydrofolaten in der natürlichenstereoisomeren Form zur Herstellung einer pharmazeutischenZubereitung geeignet zur Beeinflussung des Homocystein-Spiegels.
CH693905A5 (de) * 1999-04-15 2004-04-15 Eprova Ag Stabile kristalline Salze von 5-Methyltetrahydrofolsäure.
SI2245032T1 (sl) 2008-02-20 2015-08-31 Gnosis S.P.A., Folati, sestavki in njihove uporabe
WO2013025203A1 (en) * 2011-08-16 2013-02-21 Watson Laboratories, Inc. Resolution of tetrahydrofolic acid derivatives
ITMI20111808A1 (it) 2011-10-05 2013-04-06 Ati S R L Composizione alimentare priva di glutine e prodotti alimentari con essa preparati
CN104557937B (zh) * 2012-01-20 2017-03-08 连云港金康和信药业有限公司 (6s)‑5‑甲基四氢叶酸盐晶型及其制备方法
ES2715599T3 (es) * 2012-01-20 2019-06-05 Lianyungang Jinkang Hexin Pharmaceutical Co Ltd Forma de cristal de sal de (6S)-5-metiltetrahidrofolato y método para preparar esta
US20160207925A1 (en) * 2013-12-31 2016-07-21 Gianni Fracchia L-methylfolate salt preparations, medicaments, and nutritional supplements comprising such salts thereof
WO2015193778A1 (en) * 2014-06-16 2015-12-23 Mylan Laboratories Ltd. Crystalline form of levomefolate calcium

Also Published As

Publication number Publication date
JP7285785B2 (ja) 2023-06-02
RU2019133594A (ru) 2021-04-30
EP3609894A1 (en) 2020-02-19
JP2020512383A (ja) 2020-04-23
US11185545B2 (en) 2021-11-30
US20220016121A1 (en) 2022-01-20
HUE068578T2 (hu) 2025-01-28
KR102665004B1 (ko) 2024-05-09
PT3609894T (pt) 2024-08-29
EP3609894B1 (en) 2024-07-17
AU2018246265A1 (en) 2019-11-14
WO2018178141A1 (en) 2018-10-04
CN110475778A (zh) 2019-11-19
CA3058287A1 (en) 2018-10-04
RU2019133594A3 (pl) 2021-07-21
FI3609894T3 (fi) 2024-10-23
DK3609894T3 (da) 2024-09-09
AU2018246265B2 (en) 2022-07-07
KR20190136029A (ko) 2019-12-09
US12048700B2 (en) 2024-07-30
US20200030333A1 (en) 2020-01-30
PL3609894T3 (pl) 2024-12-16

Similar Documents

Publication Publication Date Title
ES2637829T3 (es) Cristales multicomponentes que comprenden dasatinib y agentes de formación de cocristales seleccionados
ES2989869T3 (es) Sal sódica cristalina de ácido 5-metil-(6S)-tetrahidrofólico
JP7296885B2 (ja) ５－メチル－（６ｓ）－テトラヒドロ葉酸の結晶性ナトリウム塩
JP2021529802A (ja) ５−メチル−（６ｓ）−テトラヒドロ葉酸およびｌ−ロイシンエチルエステルの結晶塩
JP7422124B2 (ja) ５－メチル－（６ｓ）－テトラヒドロ葉酸及びｌ－バリンエチルエステルの結晶性塩
US12221445B2 (en) Crystalline salts of 5-methyl-(6S)-tetrahydrofolic acid and amino ethyl esters
CN110461844A (zh) 5-甲基-(6s)-四氢叶酸与有机碱的结晶二元钠盐
ES2966936T3 (es) Sal cristalina que comprende ácido 5-metil-(6S)-tetrahidrofólico y 4-(2-hidroxietil)-morfolina
ES2966938T3 (es) Sal cristalina de ácido 5-metil-(6S)-tetrahidrofólico y éster etílico de L-isoleucina
HK40012006A (en) Crystalline sodium salt of 5-methyl-(6s)-tetrahydrofolic acid
HK40012007A (en) Crystalline sodium salt of 5-methyl-(6s)-tetrahydrofolic acid